# Plain Language Summary: Byron Nash Renal Medullary Carcinoma Awareness Act of 2023

This bill is about making sure people with sickle cell disease who are on Medicaid learn about a serious cancer risk they face. Renal medullary carcinoma is a rare but aggressive kidney cancer that develops at much higher rates in people with sickle cell disease compared to the general population. Right now, many people with sickle cell disease don't know about this specific cancer risk, which means they might not get screened early or watch for warning signs.

The bill works by creating financial incentives for states to educate Medicaid patients who have sickle cell disease about renal medullary carcinoma. Essentially, it tells states that if they provide this education to their Medicaid patients with sickle cell disease, the federal government will help pay for it—just like it already does for education about other serious health conditions like stroke. This means states have a financial reason to make sure their sickle cell disease patients get information about this cancer risk, potentially through doctor visits, educational materials, or other awareness programs.

Who does this affect? Primarily people with sickle cell disease who receive Medicaid benefits. For them, this could mean receiving educational materials or information from their healthcare providers about the signs and symptoms of renal medullary carcinoma, which could lead to earlier detection and better outcomes. States also benefit because they get federal funding support for running these education programs. The practical impact is that people with sickle cell disease will have better access to information about a health risk they specifically face, helping them make informed decisions about their health and potentially catch cancer earlier if it develops.

Byron Nash Renal Medullary Carcinoma Awareness Act of 2023

Green, Al

Byron Nash Renal Medullary Carcinoma Awareness Act of 2023&nbsp;[sic]This bill allows states to receive federal payment under Medicaid for 50% of their costs for providing education on the risk of renal medullary carcinoma to individuals with sickle cell disease. (Renal medullary carcinoma is a rare kidney disease usually found in individuals with the sickle cell trait.)